This January, see change in action at the 2022 NF Congressional Briefing! Hear from congresspeople, researchers, and NF patients working to raise NF awareness and secure research funding. Our team will address the CDMRP, National Institutes of Health, and other public and private research partnerships, whose work helped lead to 2020’s first-ever FDA-approved drug for neurofibromatosis type 1. Sit in on the conversations that set things in motion and transform lives! Join our Senate meeting on January 6 or House of Representatives meeting on January 7. Registration link to follow.